Evidence map›Paper›PMID 40074510›Full record

ReviewBest practice & research. Clinical haematology2024

Analyte heterogeneity analysis as a possible potency parameter for MSC.

David Kaplan, Eric Christian, Sarah Planchon Pope, Hillard M Lazarus, Jeffrey A Cohen

Abstract readReview
In one paragraph

Review in Best practice & research. Clinical haematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

David KaplanCellPrint Biotechnology, LLC, United States. Electronic address: david.kaplan@case.edu.
Eric ChristianCellPrint Biotechnology, LLC, United States.
Sarah Planchon PopeMellen Center, Neurological Institute, Cleveland Clinic Foundation, United States.
Hillard M LazarusCellPrint Biotechnology, LLC, United States; Department of Medicine, Case Western Reserve University, United States.
Jeffrey A CohenMellen Center, Neurological Institute, Cleveland Clinic Foundation, United States.

Funding

Immunobiology of mesenchymal stem cell transplantation in multiple sclerosisR01NS074787 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI COHEN, JEFFREY ALAN · 2011 to 2014
$1.2M
NINDS NIH HHS R01 NS074787
6 · The paper itself

Abstract

Mesenchymal stem/stromal cells (MSC) have been transplanted for therapeutic purposes with inconsistent results. MSC preparations are heterogeneous, and this person-to-person heterogeneity may account for the variable clinical outcomes. Additionally, the mechanisms of therapeutic action for MSC are unclear which confounds attempts to understand and identify factors that may account for variable clinical results. Here, we report our analysis of MSC preparations for the expression levels of molecules that have been hypothesized to mediate MSC function. Although most of the analytes assessed demonstrated little divergent expression, several molecules were found with enhanced heterogeneity both within individual MSC preparations and among MSC preparations from the sample of multiple sclerosis patients. The variable expression of these molecules may relate to the therapeutic heterogeneity of MSC. Additionally, we found a novel set of molecules that were highly intercorrelated in MSC. The tight association of this group of molecules may represent an invariant molecular organization that is integral to MSC activity. The precise analysis of molecular expression levels in MSC has the potential to answer concerns about variable therapeutic effects of MSC transplantation as well as to understand the mechanism of clinical effects.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationMultiple SclerosisAdultFemaleHumansMaleAnalyte expression heterogeneityCorrelationFlow cytometryMesenchymal stromal cellsMultiple sclerosis

Identifiers

PMID40074510
PMCPMC11904128

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.